Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ | Pancreas cancer…

Explore the latest developments concerning Pill to treat.

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ | Pancreas cancer

Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing

A pill that can shrink and potentially eliminate pancreas tumours is being hailed as the biggest breakthrough treatment for the cancer in decades.

In one in 12 of the patients given the drug, daraxonrasib, during a trial, the cancer became undetectable, and the tumours stopped growing in almost all of the 61 patients. The trial participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

Though doctors have said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they have said it is encouraging news because it appears it will offer patients more time, even if it does not cause full remission.

Black Kitchen Sink Faucet Pull Down Hot and Cold Water Mixer2 Mode Tap with Dual Spout 360 Rotation Flexible Deck Mounted

Black Kitchen Sink Faucet Pull Down Hot and Cold Water Mixer2 Mode Tap with Dual Spout 360 Rotation Flexible Deck Mounted
Click for more info. »

Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting

Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer

REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC). The data will be presented today during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

For more detailed information, explore updates concerning Pill to treat.

For more news…

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *